Free Trial

Vericel Q4 2023 Earnings Report

Vericel logo
$58.24 -0.50 (-0.85%)
(As of 12/3/2024 ET)

Vericel EPS Results

Actual EPS
$0.26
Consensus EPS
$0.18
Beat/Miss
Beat by +$0.08
One Year Ago EPS
$0.12

Vericel Revenue Results

Actual Revenue
$65.00 million
Expected Revenue
$64.28 million
Beat/Miss
Beat by +$720.00 thousand
YoY Revenue Growth
+23.30%

Vericel Announcement Details

Quarter
Q4 2023
Time
Before Market Opens
“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Vericel Earnings Headlines

Vericel (NASDAQ:VCEL) Price Target Raised to $66.00
WARNING: “Buffett Indicator” flashing for first time in 50 years
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Leerink Partners Sticks to Its Buy Rating for Vericel (VCEL)
Vericel price target raised to $66 from $56 at BTIG
See More Vericel Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vericel? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vericel and other key companies, straight to your email.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

View Vericel Profile

More Earnings Resources from MarketBeat